Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 59, Issue 119, 2012, Pages 2264-2268

  Hirano, Genryu ^a   Sakurai, Kunitoshi ^a   Sohda, Tetsuro ^a   Kunimoto, Hideo ^a   Yotsumoto, Kaoru ^a   Fukunaga, Atsushi ^a   Iwashita, Hideyuki ^a   Ueda, Shuichi ^a   Yokoyama, Keiji ^a   Morihara, Daisuke ^a   Takeyama, Yasuaki ^a   Sakamoto, Masaharu ^a   Irie, Makoto ^a   Iwata, Kaoru ^a   Shakado, Satoshi ^a   Sakisaka, Shotaro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Carboplatin; Extrahepatic metastasis; Hepatocellular carcinoma; Systemic chemotherapy

Indexed keywords

CARBOPLATIN; FLUOROURACIL; SORAFENIB;

ADRENAL METASTASIS; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER FAILURE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODAL CHEMOTHERAPY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT RESPONSE; VOMITING;

ADRENAL GLAND NEOPLASMS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARBOPLATIN; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LOGISTIC MODELS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872067213     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12030     Document Type: Article

References (21)

1. Poon RT, Fan ST, Tsang FH, Wong J: Local regional therapies for hepatocellular carcinoma: a critical rexiew form surgeon's perspective. Ann Surg 2002; 235:466-486.
2. Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K: Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology 1992; 16:112-117.
3. Nowak AK, Chow PK, Findlay M: Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004; 40:1474-1484.
4. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442.
5. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
6. Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
8. th August 2006.
9. Therasse P, Afbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
10. Kiyokawa K, Umemura T, Ichijo T, et al.: Hepatocellular carcinoma: Recent trends in Japan. Gastroenterology 2004; 127:S17-26.
11. Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35:519-524.
12. Llovet JM, Bustamante J, Castells A, et al.: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62-67.
13. Lee CY, Bae MK, Park IK, et al.: Surgical resection for pulmonary metastasis from hepatocellular carcinoma: analysis of prognosis in relation to primary control. J Surg Oncol 2010; 101:239-243.
14. Park SH, Lee Y, Han SH, et al.: Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 2006; 6:3.
15. Chung YH, Song IH, Song BC, et al.: Combined therapy consisting of intra-arterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88:1986-1991.
16. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial).) Clin Oncol 2007; 25:18S LBA1.
17. Cheng AL, Kang YK, Chen Z, et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
18. Sherman M, Mazzaferro V, Amadori D, et al.: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: a subanalysis from the SHARP trial. J Clin Oncol 2008; 26:4584. (Abstract).
19. Genryu H, Tetsuro S, Shotaro S, et al.: Effectiveness of systemic chemotherapy using CBDCA and 5-FU in a case of hepatocellular carcinoma with metastases to the lung. Kanzo 2011; 52:42-49. (In Japanese with English abstract).
20. Yamashita F, Tanaka M, Andou E, et al.: Carboplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Oncology 1997; 54:28-33.
21. Okada S: Chemotherapy in hepatocellular carcinoma. Hepatogastroenterol 1998; 45:1259-1263.